Skip To Main Content
David Barrett on Muck Rack

David Barrett

United Kingdom
As seen in: The Catholic Herald, MSN, Color Research & Application, Daily Mail, Fandom, Nature, Scottish Daily Mail, Nurse Education in Practice, MDPI, Sydney Morning Herald, Taylor & Francis Online and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM

|
By Nelson F. Freeburg, Daniel Chafamo, Gayathri Konanur Gopikrishna, Regan Murphy, Jacqueline Peng, Shridhar Parthasarathy, Sydney Dumont, Edward G Estrada, Meghan T. Logun, Yusha Sun, Xin Wang, Payal Grover, Jesse Rodriguez, Daniel Zhang, Kristen Park, Yao Fu, Nadine Ben Hamouda, Isaias Hernandez-Verdin, Lamia Lamrani, Kelly Hicks, Natalie Cooper, Christina Ekwegbara, Emma Bawden, Joshua J. Waterfall, Jaime Fuentealba, Marion Alcantara, John T Seykora, Stephen Prouty, David Barrett, esha banerjee, Arin Cox, Charles-Antoine Assenmacher, Camilla Macia, Melinda Yin, Erica Carpenter, Guo-li Ming, Catherine Sautès-Fridman, Wolf H. Fridman, Eric Tartour, E. John Wherry, Sebastian Amigorena, Joseph A Fraietta, MacLean P. Nasrallah, Hongjun Song, Tyler Miller, Stephen J. Bagley, Donald M. O’Rourke, Zev A. Binder, Cécile Alanio, Dana Silverbush
| Cell Press Verified
Keywords CAR T cell therapy glioblastoma longitudinal dynamics tumor microenvironment immunotherapy biomarkers immunology single-cell transcriptomics NK cells regulatory T cells myeloid immunosuppression Introduction Although chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies,1,2 translating this success to solid tumors has proven challenging.3,4 Key barriers include antigen paucity, inefficient T cell trafficking, tumor heterogeneity,...
Open in Who Shared Issue with article?

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM

|
By Nelson F. Freeburg, Daniel Chafamo, Gayathri Konanur Gopikrishna, Regan Murphy, Jacqueline Peng, Shridhar Parthasarathy, Sydney Dumont, Edward G Estrada, Meghan T. Logun, Yusha Sun, Xin Wang, Payal Grover, Jesse Rodriguez, Daniel Zhang, Kristen Park, Yao Fu, Isaias Hernandez-Verdin, Kelly Hicks, Natalie Cooper, Emma Bawden, Joshua J. Waterfall, Jaime Fuentealba, Marion Alcantara, John T Seykora, Stephen Prouty, David Barrett, esha banerjee, Charles-Antoine Assenmacher, Erica Carpenter, Guo-li Ming, Catherine Sautès-Fridman, Wolf H. Fridman, Eric Tartour, E. John Wherry, Sebastian Amigorena, Joseph A Fraietta, MacLean P. Nasrallah, Hongjun Song, Tyler Miller, Stephen J. Bagley, Donald M. O’Rourke, Zev A. Binder, Cécile Alanio, Dana Silverbush, Nadine Ben Hamouda, Lamia Lamrani, Christina Ekwegbara, Arin Cox, Camilla Macia, Melinda Yin
| Cell Press Verified
Keywords CAR T cell therapy glioblastoma longitudinal dynamics tumor microenvironment immunotherapy biomarkers immunology single-cell transcriptomics NK cells regulatory T cells myeloid immunosuppression Introduction Although chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies,1,2 translating this success to solid tumors has proven challenging.3,4 Key barriers include antigen paucity, inefficient T cell trafficking, tumor heterogeneity,...
Open in Who Shared Issue with article?

Preguntas y Respuestas con David Barrett

|
By David Barrett
| Pharmaceutical Technology MX Verified
CÁPSULAS FARMACÉUTICAS PyRcon David Barrett, director de operaciones en cut-e La industria farmacéutica ha experimentado muchos problemas de calidad ligados a errores en la manufactura. Las compañías están gastando millones de dólares cada año para entrenar, re-entrenar  y evaluar el conocimiento de las cGMPs de sus operadores y técnicos.
Open in Who Shared Issue with article?
See all 101 licensed articles (110 Total)